APA aipamena

Kamata, T., Suzuki, A., Mise, N., Ihara, F., Takami, M., Makita, Y., . . . Motohashi, S. (2016). Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells. Cancer Immunol Immunother.

Chicago Style aipamena

Kamata, Toshiko, et al. "Blockade of Programmed Death-1/programmed Death Ligand Pathway Enhances the Antitumor Immunity of Human Invariant Natural Killer T Cells." Cancer Immunol Immunother 2016.

MLA aipamena

Kamata, Toshiko, et al. "Blockade of Programmed Death-1/programmed Death Ligand Pathway Enhances the Antitumor Immunity of Human Invariant Natural Killer T Cells." Cancer Immunol Immunother 2016.